At a glance
The Division of Tuberculosis (TB) Elimination publishes Dear Colleague Letters from the Division to partners about TB updates. Dear Colleague Letters are available from the past three years.
2024
CDC published "Reported Tuberculosis in the United States, 2023."
"Tuberculosis — United States, 2023" has information on provisional U.S. TB disease cases in 2023.
2023
CDC's Tuberculosis Trials Consortium (TBTC) launched a new international clinical trial.
CDC published "Reported Tuberculosis in the United States, 2022."
CDC announced new resources about the Uniting for Ukraine program TB screening requirements.
Beginning May 24, 2023, CDC implemented rapid testing for fluoroquinolone (FQ) resistance.
CDC encourages TB program to take proactive measures to reduce drug supply interruptions.
CDC updated the 2022 Provisional Guidance for the BPaL Regimen to Treat Drug-resistant TB Disease.
Read a message for World TB Day 2023 from Dr. Rochelle P. Walensky, CDC Director.
CDC's Division of TB Elimination shares information to assist in World TB Day 2023 planning efforts.
2022
U.S. tuberculosis (TB) programs have until December 31, 2022 to implement the new TB reporting form.
"Reported Tuberculosis in the United States, 2021" has information on U.S. TB disease cases.
Selected TB Centers of Excellence for Training, Education, and Medical Consultation (TB COE).
Letter about health requirements for Venezuelans entering the United States under a new program.
CDC information on the timing of TST or IGRA in relation to the JYNNEOS vaccine.
CDC provides information for TB programs if drug-resistant latent TB infection is presumed.
This letter describes the TB screening requirements for the Uniting for Ukraine Program.
Read a message for World TB Day 2022 from Dr. Rochelle P. Walensky, CDC Director.
CDC announces the Think. Test. Treat TB Campaign to raise awareness of latent TB infection.
CDC released interim guidance on a four-month TB treatment regimen.
CDC has guidance on using bedaquiline, pretomanid, and linezolid to treat drug-resistant TB disease.
A 2022 publication found that electronic DOT is noninferior to in-person DOT.
Resources from CDC's Division of TB Elimination to assist in World TB Day 2022 planning efforts.
This letter shares updated CDC definitions for extensively drug-resistant (XDR) and pre-XDR TB